Arrowhead Pharmaceuticals (ARWR) said Monday that Redemplo is now available in Germany to treat adults with Familial Chylomicronaemia Syndrome (FCS), or dangerously high levels of triglycerides in the bloodstream.
Following its marketing authorization by the European Commission in June, Redemplo is now listed in the Lauer-Taxe database and thus able to be prescribed, dispensed and reimbursed in Germany, the company said.
Arrowhead shares were 1.1% higher in Monday trading.
Price: $87.26, Change: $+0.61, Percent Change: +0.71%